Practical Guidance for the Expanded Implementation and Provision of Bispecific Antibodies for Diffuse Large B-Cell Lymphoma (DLBCL) Across Canada.
Simple Summary: Bispecific antibodies (BsAbs) are a relatively new treatment option for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). There is an opportunity to provide these medications in the community, with greater convenience for patients, but establishing such programs requires...
| Publicado en: | Current Oncology Vol. 32; no. 8; pp. 460 - 481 |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Aug2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |